Home    Contact Us    Send to Colleague    Search 

11 May 2017
CHP client signs an agreement to commercialize its 505(b)(2) asset for the treatment of glaucoma.
"CHP client signs an agreement to commercialize its 505(b)(2) asset for the treatment of glaucoma.  The product is currently undergoing FDA review."

Return to Press Releases

© 2019 by Commercial Healthcare Partners. Website Design & Development by Birchwood Group   Commercial Healthcare Partners    Jim Usry